Under the development boom of innovative drug research and development of pharmaceutical companies, market risks are becoming more and more obvious.

"Pharmaceutical Network Market Analysis" In recent years, the concept of innovative drugs is very hot, pharmaceutical listed companies have transformed to do innovative drugs.
The reason is nothing more than chemical drugs affected by consistent evaluation, the price advantage of the first imitation is gone, another collection of sharp price reduction, as well as Chinese medicine is subject to auxiliary drugs, medical insurance control fees, the entire pharmaceutical industry profit decline.
addition, coupled with recent years, the state has continuously introduced policies to encourage drug innovation, drug enterprises innovation and development has obviously become a trend, especially high-tech barriers to innovative drugs have clearly become the pharmaceutical companies have become the layout of research and development direction.
Such as Hengrui Pharmaceutical as a domestic innovative national pharmaceutical enterprises, over the years based on a global perspective, in accordance with international standards to promote technological innovation, will be "going out", "introducing" combined, and vigorously introduce advanced technology, intelligent brain and global resources at the same time, but also to accelerate the domestic innovative pharmaceutical technology, brand and health cause into the world, two-pronged, two-way efforts to further promote the national pharmaceutical competitiveness upgrade.
2020, Watson Pharmaceuticals announced that its board of directors had decided to appoint Yuxun Wang as the company's deputy general manager, responsible for the company's research and development, mainly responsible for capacity-building in the company's innovative pharmaceutical sector.
and use its academic and clinical research experience in the field of cancer to effectively promote the company's independent research and development of innovative pharmaceutical products and innovative drug BD-related work.
Then in July, asia-pacific pharmaceutical industry in response to investors' questions also said that it will actively carry out high-end generic drugs, innovative drug research and development work, and will focus on research and development focus on anti-tumor, anti-infection and other core areas, with independent intellectual property rights to improve the development of new drugs, layout of new preparation varieties.
as a whole, "creative imitation combination" is the development path that most pharmaceutical companies choose to innovate.
, it's worth noting that making innovative drugs isn't that easy.
most drug companies choose ME-TOO, or known hot targets, the likelihood of failure is often very high.
rule group, the phase II clinical trial of alpha monoclonal antibody, a recombinant humanized anti-human tumor necrotic cause of death, was completed in 2018 and no description of the product was found in the 2019 annual report.
The reason for this is that Lizhu's anti-human tumor necrotic cause alpha monoclonal antibody is an innovative drug, not much confidence in the phase III PK trial, coupled with the high clinical cost of phase III, there is no need to continue.
also shanghai medicine, in 2014 recombinant human tumor necrotizing child mutant mutant-Fc fusion protein injection obtained clinical trial approval.
phase I clinical study, no suitable method was found to increase the blood drug concentration of the patients in the group, and the project was terminated, with a cumulative investment of 6,973.55 million yuan.
, drug updates are iterating too quickly, and not all innovative drugs can help drug companies succeed.
addition, many enterprises do not yet have this ability, after all, innovative drug research and development itself is expensive, long cycle, there is a very high risk of failure of research and development of new products.
, the industry believes that, in the context of the state to encourage innovation, collection and other policies, pharmaceutical enterprises transformation and innovation can not be blind, to reasonable layout, maintain focus, endure loneliness.
.